CTLA4 and colorectal carcinoma: In conclusion, the efficacy of targeting anti-CTLA-4 as a monotherapy in CRC may be limited, emphasizing the potential for enhanced effectiveness through combination with other immune checkpoint inhibitors, such as anti-PD-L1.